Nanobiotix is trading 5.9% up now at $43.10 after biotech-sector strength lifted sentiment.
- Biotech is rising 3.73%, supported by Moderna’s positive personalized cancer-vaccine Phase 3 results, providing the clearest explanation for Nanobiotix’s move.
- The company’s investor-relations page shows no new August 19, 2026 announcement; its latest listed update was dated August 7, 2026.
- No volume data was provided.